Publicacións en colaboración con investigadores/as de Universitat Pompeu Fabra (8)

2023

  1. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

    Therapeutic Advances in Medical Oncology, Vol. 15

2019

  1. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

    European Journal of Cancer, Vol. 120, pp. 54-64

  2. The role of clonal communication and heterogeneity in breast cancer

    BMC Cancer, Vol. 19, Núm. 1

2018

  1. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

    Oncotarget, Vol. 9, Núm. 41, pp. 26406-26416

2017

  1. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse

    Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044

  2. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients

    Annals of Oncology, Vol. 28, Núm. 6, pp. 1325-1332

2016

  1. High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer

    Oncologist, Vol. 21, Núm. 2, pp. 150-155

2014

  1. Predicting response and survival in chemotherapy-treated triple-negative breast cancer

    British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541